FMP
Eton Pharmaceuticals, Inc.
ETON
NASDAQ
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
12.45 USD
0.48 (3.86%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
11.65M
10.32M
9.07M
7.97M
5.17M
4.02M
3.45M
2.96M
6.48M
6.3M
5.63M
5.01M
5.85M
5.79M
8.56M
5.81M
-871k
505k
2.97M
651k
6.72M
5.29M
5.59M
5.16M
0
0
0
0
6.72M
5.29M
5.59M
5.16M
0
0
0
0
629k
509k
-2.94M
-800k
-1.14M
-8k
-52k
-11k
-511k
501k
-2.99M
-811k
87k
-126k
54k
208.72k
-598k
627k
-3.04M
-811k
-0.02
0.02
-0.12
-0.03
-0.02
0.02
-0.12
-0.03
26.14M
25.9M
25.78M
25.76M
26.14M
26.55M
25.78M
25.76M
984k
509k
-2.66M
-548k
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-107.3M
-107.92M
-104.88M
-104.07M
-598k
627k
-3.04M
-811k
0
0
0
0
0
0
0
0
-107.89M
-107.3M
-107.92M
-104.88M
-598k
627k
-3.04M
-811k
2024 Q4
2024 Q3
2024 Q2
2024 Q1
209k
226k
255k
131k
355k
0
279k
252k
-8.13M
1.87M
0
-1.88M
7.99M
-1.64M
-24k
1.76M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.